Title |
Poor Visual Outcome After First Attack in a Cohort of Patients With Myelin Oligodendrocyte Glycoprotein-Related Optic Neuritis |
Creator |
Armin Handzic; Sumana Naidu; Natalie Brossard-Barbosa; Edward Margolin |
Affiliation |
Faculty of Medicine (AH, NB-B, EM), Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; Faculty of Medicine (EM), Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada; and Temerty Faculty of Medicine (SN), University of Toronto, Toronto, Canada |
Abstract |
Background: Myelin oligodendrocyte glycoprotein-associated optic neuritis (MOG-ON) is typically a highly treatable condition that responds quickly to treatment with high doses of corticosteroids. We reviewed the cohort of patients with MOG-ON to identify patients who had poor visual outcome after the first attack despite rapid initiation of treatment. Methods: Records of all patients diagnosed with MOG-ON seen in a tertiary neuro-ophthalmology practice were reviewed to identify and describe those with poor visual recovery (final visual acuity of 20/200 or worse in at least one eye) after the first attack despite initiation of treatment within 1 week of symptoms onset. Results: Two patients of 36 fulfilled inclusion criteria: both had bilateral severe optic neuritis at presentation, and both were seen within 7 days of symptoms onset and treated immediately with pulse doses of intravenous corticosteroids followed by very-slow oral taper. Plasma exchange (PLEX) was performed 2 weeks after symptoms onset in both patients because of poor response to steroids, followed by monthly intravenous immunoglobulin infusions. Despite the use of all available treatment modalities, final visual outcome was poor in both patients. In both patients, there was enhancement of intracanalicular portion of optic nerve in the worse-seeing eye. Conclusions: In this cohort of patients with MOG-ON, 2 (5.6%) had very poor visual outcome after the first attack despite immediate initiation of treatment with pulse doses of corticosteroids and subsequent treatment with PLEX. These cases highlight that despite immediate initiation and escalation of treatment, some patients with MOG-ON can have very poor visual outcomes after the initial attack that may be because of the involvement of the intracanalicular portion of the optic nerves. |
Subject |
Female; Glucocorticoids / administration & dosage; Glucocorticoids / therapeutic use; Humans; Magnetic Resonance Imaging; Male; Myelin-Oligodendrocyte Glycoprotein / immunology; Optic Nerve / diagnostic imaging; Optic Neuritis / diagnosis; Optic Neuritis / drug therapy; Optic Neuritis / physiopathology; Retrospective Studies; Visual Acuity / physiology |
Date |
2024-06 |
Date Digital |
2024-06 |
References |
Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8-15. Lu Q, Luo J, Hao H, et al. Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol. 2021;268:4537-4548. Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6:e572. Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128-3138. Jarius S, Ruprecht K, Kleiter I, et al. In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280. |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Publication Type |
Journal Article |
Source |
Journal of Neuro-Ophthalmology, June 2024, Volume 44, Issue 2 |
Collection |
Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/ |
Publisher |
Lippincott, Williams & Wilkins |
Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
Rights Management |
© North American Neuro-Ophthalmology Society |
ARK |
ark:/87278/s6r3cpcd |
Setname |
ehsl_novel_jno |
ID |
2721550 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6r3cpcd |